An update from Celadon Pharmaceuticals PLC ( (GB:CEL) ) is now available.
Celadon Pharmaceuticals Plc has announced a financial position update, highlighting the receipt of the final £103k from a £1.0m credit facility draw down and a £389k tax credit from a 2022 R&D claim. The company, which focuses on cannabis-based medicines, continues to explore additional capital opportunities.
More about Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals Plc is a UK-based company that specializes in the development, production, and sale of cannabis-based medicines. The company focuses primarily on improving the quality of life for chronic pain sufferers and exploring treatments for conditions like autism. Its EU-GMP approved facility facilitates cultivation, extraction, and research, and it holds a Home Office license for commercial supply. Celadon also participates in clinical trials for cannabis-based treatments and holds a stake in Kingdom Therapeutics, which is working on cannabinoid medicine for autism.
YTD Price Performance: 20.0%
Average Trading Volume: 168,024
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £13.08M
For a thorough assessment of CEL stock, go to TipRanks’ Stock Analysis page.